Skip to main content

Market Overview

Charlie Rowand

  • Analyst Color, AUPH, Biotech, Charlie Rowand, News, Voclosporin

    Aurinia's Path Forward

    Tuesday, November 15, 2016 - 4:06pm

    On November 2, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) announced the successful completion of their end-of-Phase II meeting with the FDA and plans for a single Phase III clinical trial for fast-track-designated Voclosporin. Shares are up over 30 percent since then. There are an estimated 115,000...

    Read More...